BCM
LEGN icon

Bayesian Capital Management’s Legend Biotech LEGN Stock Holding History

Bayesian Capital Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,600
Closed -$247K – 797
2024
Q4 		$247K Buy
+7,600
New +$315K 0.03% 525
2024
Q3 		– Sell
-5,741
Closed -$254K – 884
2024
Q2 		$254K Buy
+5,741
New +$265K 0.03% 546
2024
Q1 		– Sell
-10,906
Closed -$656K – 964
2023
Q4 		$656K Buy
+10,906
New +$691K 0.07% 327

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Bayesian Capital Management's LEGN Position: Q1 2025 in Review

Bayesian Capital Management sold out of Legend Biotech (LEGN) in Q1 2025, closing a stake of 7,600 shares — an estimated $247K sold.

Bayesian Capital Management first reported a position in LEGN in Q4 2023 and held it in 3 quarters. The position peaked at $656K in Q4 2023. 208 funds tracked by Wall St. Rank hold LEGN as of Q1 2025.

  • Bayesian Capital Management reported no remaining Legend Biotech position as of Q1 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 7,600 Legend Biotech shares in Q1 2025, an estimated $247K.
  • Bayesian Capital Management first reported a position in Legend Biotech in Q4 2023 and held it in 3 quarters.
  • Bayesian Capital Management's Legend Biotech position peaked at $656K in Q4 2023.
  • 208 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2025.

Based on Bayesian Capital Management's 13F filing for Q1 2025, filed 15 May 2025.